1-3 of 3
Carol Oerth
Close
Sort by
Journal Articles

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

Donna M. Weber, Sundar Jagannath, MD, Ronald Sobecks, Gary Schiller, Lisa Chiacchierini, David Reiser, Carol Oerth, Jose Garcia-Vargas, Syed Rizvi
Journal: Blood
Blood (2008) 112 (11): 3711.
https://doi.org/10.1182/blood.V112.11.3711.3711
Published: 2008
Journal Articles

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

Donna M. Weber, Sundar Jagannath, Amitabha Mazumder, Ronald Sobecks, Gary J. Schiller, Maria Gavino, Chantelle Sumbler, Carrie McFadden, Cong Chen, Justin L. Ricker, Syed Rizvi, Carol Oerth, Patricia Brownell, Mohamad A. Hussein
Journal: Blood
Blood (2007) 110 (11): 1172.
https://doi.org/10.1182/blood.V110.11.1172.1172
Published: 2007
Journal Articles

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, Carol Oerth, Barbara Atkins, Ivy Fearen, Kenneth C. Anderson, David S. Siegel
Journal: Blood
Blood (2007) 110 (11): 1179.
https://doi.org/10.1182/blood.V110.11.1179.1179
Published: 2007